

**Mo-99 2016 TOPICAL MEETING ON
MOLYBDENUM-99 TECHNOLOGICAL DEVELOPMENT**

SEPTEMBER 11-14, 2016

THE RITZ-CARLTON

ST. LOUIS, MISSOURI

**Coqui RadioPharmaceuticals Corp., Progress and Perspective on
the U.S. Domestic Supply of Mo-99**

Carmen I. Bigles

Coqui RadioPharmaceuticals Corp.

1172 South Dixie Hwy., #335, Coral Gables, FL 33146 – USA

ABSTRACT

In 2009 Coqui Radiopharmaceuticals Corp (Coqui) was created with the vision of solving the United States M-99 supply shortage. Coqui plans to build two open-pool reactors LEU/LEU, multiple Mo-99 production lines, a waste conditioning plant, a radiopharmaceutical production plant, nuclear and medical support services and administrative offices.

Throughout Coqui's evolutions, the principals have managed the challenges of deploying such a facility conscientious of risk management's importance. They have learned to problem solve.

Coqui designed a risk management weighted table consisting of: LEU technology, Mo-99 process, market adoption, government support (DOE), supportive site, NRC approval, FDA approval, CMS reimbursement, business model robustness, timeline risk and capital raising.

Our mission and motivation is to solve the Mo-99 shortage that comprises medical treatment integrity so that the medical profession can effectively meet the patients care needs.